The price of BridgeBio Pharma Inc (NASDAQ:BBIO) shares last traded on Wall Street rose 5.33% to $38.36.
BBIO stock price is now 12.20% away from the 50-day moving average and 31.38% away from the 200-day moving average. The market capitalization of the company currently stands at $7.28B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $50, Redburn Atlantic recently initiated with Buy rating for BridgeBio Pharma Inc (NASDAQ: BBIO). , while ‘Oppenheimer’ rates the stock as ‘Perform’
In other news, Kumar Neil, Chief Executive Officer sold 75,000 shares of the company’s stock on Apr 22 ’25. The stock was sold for $2,558,025 at an average price of $34.11. Upon completion of the transaction, the Chief Executive Officer now directly owns 4,873,447 shares in the company, valued at $186.95 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 14 ’25, Director Ellis Andrea sold 10,000 shares of the business’s stock. A total of $350,000 was realized by selling the stock at an average price of $35.00. This leaves the insider owning 12,000 shares of the company worth $0.46 million. A total of 18.24% of the company’s stock is owned by insiders.
During the past 12 months, BridgeBio Pharma Inc has had a low of $21.62 and a high of $39.47. The fifty day moving average price for BBIO is $34.19 and a two-hundred day moving average price translates $29.198425 for the stock.
The latest earnings results from BridgeBio Pharma Inc (NASDAQ: BBIO) was released for 2025-03-31. The company reported revenue of $116.63 million for the quarter, compared to $211.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -44.76 percent.
